The State Food and Drug Administration (SFDA) was Chinaís former national regulator for drugs and medical devices and is now succeeded by the National Medical Products Administration (NMPA).
This authority oversees clinical trial authorization, safety reporting expectations, and approval pathways for studies conducted in China. Sponsors running multinational trials must align local submissions, ethics approvals, and importation requirements with the Chinese regulatory framework. Differences in data standards, timelines, and inspection practices can affect global development strategy and study operations. Understanding SFDA/NMPA expectations helps reduce delays and strengthens compliance for China-involved programs.